Chance of more international honor for Genmab
Second year in a row, Danish biotech Genmab can potentially be crowned as the world’s best biotech company at the Scrip Awards 2017 in London in November. Like last year, CEO Jan van de Winkel is also nominated as Executive of the Year and so is another Danish top manager.
BY MARTIN HAVTORN PETERSEN
It will probably not have escaped the attention of players in the Danish life science-industry that the biotech company Genmab has done quite well for itself in recent years. Genmab has also caused ripples abroad, which was seen once again last week when the news- and analysis group Scrip Pharmaintelligence, covering the international medical- and biotech business, announced the nominees in its annual awards ceremony.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Darzalex is still the “star of the show” for Genmab
For abonnenter
Genmab’s cash cow obtains new approval
For abonnenter
Janssen initiates new combination study of Genmab-drug
For abonnenter
